The quality of life during intravesical bacillus Calmette-Guerin therapy

Journal of Urology

Volumn 155, Issue 4, 1996, Pages 1221-1226

  Böhle, Andreas ^a   Balck, Friedrich ^a   Von Wietersheim, Jörn ^a   Jocham, Dieter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

BCG vaccine; bladder neoplasms; immunotherapy; quality of life

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; MICTURITION DISORDER; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT;

EID: 0029930046     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66224-4     Document Type: Article

References (24)

1. Lamm, D. L., Crawford, E. D., Blumenstein, B., Crissman, J., deVere White, R., Wolf, M., Lowe, B., Sarosdy, M., Schellhammer, P., Sagalowsky, A., Smith, J., Grossman, H. B., Flanigan, R., Moon, T., Brendler, C. and Coltman, C.: SWOG 8795: a randomized comparison of bacillus Calmette-Guérin and mitomycin C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder. J. Urol., part 2, 149: 282A, abstract 275, 1993.
2. Lamm, D. L.: Carcinoma in situ. Urol. Clin. N. Amer., 19: 499, 1992.
3. Lamm, D. L.: Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. N. Amer., 19: 573, 1992.
4. el-Demiry, M. I. M., Smith, G., Ritchie, A. W. S., James, K., Cumming, J. A., Hargreave, T. B. and Chisholm, G. D.: Local immune responses after intravesical BCG treatment of carcinoma in situ. Brit. J. Urol., 60: 543, 1987.
5. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol., 147: 1636, 1992.
6. Böhle, A., Nowc, Ch., Ulmer, A. J., Musehold, J., Gerdes, J., Hofstetter, A. G. and Flad, H.-D.: Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J. Urol., 144: 59, 1990.
7. Böhle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. and Flad, H.-D.: Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol., 144: 53, 1990.
8. Lamm, D. L.: Complications of bacillus Calmette-Guérin immunotherapy. Urol. Clin. N. Amer., 19: 565, 1992.
9. Lamm, D. L., Stogdill, V. D., Stogdill, B. J. and Crispen, R. G.: Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J. Urol., 135: 272, 1986.
10. Heinisch, M., Ludwig, M. and Bullinger, M.: Psychometrische Testung der Münchner Lebensqualitäts Dimensionen Liste (MLDL). In: Lebensqualität bei kardiovaskulären Erkrankungen. Edited by M. Bullinger, M. Ludwig and N. V. Steinbüchel. Göttingen: Hogrefe, pp. 73-90, 1991.
11. Bullinger, M.: Forschungsinstrumente zur Erfassung der Lebensqualität bei Krebs - ein Überblick. In: Jahrbuch der medizinischen Psychologie III. Psychosoziale Onkologie. Edited by R. Verres and M. Hasenbring. Berlin: Springer Verlag, pp. 45-57, 1989.
12. Aaronson, N. K., Bullinger, M. and Ahmedzai, S.: A modular approach to quality-of-life assessment in cancer clinical trials. In: Cancer Clinical Trials: A Critical Appraisal. Edited by H. Scheurlen, R. Kay and M. Baum. Berlin: Springer Verlag, pp. 231-249, 1988.
13. Böhle, A., Schüller, J., Knipper, A. and Hofstetter, A.: Bacillus Calmette-Guérin treatment and vesicorenal reflux. Eur. Urol., 17: 125, 1990.
14. Glatzer, W. and Zapf, W.: Lebensqualität in der BRD. Objektive Lebensbedingungen und subjektives Wohlbefinden. Frankfurt/Main: Campus Verlag, 1984.
15. Fosså, S. D., Aaronson, N., Calais da Silva, F., Denis, L., Newling, D., Hosbach, G. and Kaalhus, O.: Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. Eur. Urol., 16: 335, 1989.
16. Aaronson, N. K., Bullinger, M. and Ahmedzai, S.: A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res., 111: 231, 1988.
17. Nordström, G., Nyman, C. R. and Theorell, T.: Psychosocial adjustment and general state of health in patients with ileal conduit urinary diversion. Scand. J. Urol. Nephrol., 26: 139, 1992.
18. Raghavan, D., Grundy, R. and Lancaster, L.: Assessment of quality of life in long-term survivors treated by first-line intravenous cisplatin for invasive bladder cancer. Prog. Clin. Biol. Res., 260: 625, 1988.
19. Månsson, A., Johnson, G. and Månsson, W.: Quality of life after cystectomy. Comparison between patients with conduit and those with continent caecal reservoir urinary diversion. Brit. J. Urol., 62: 240, 1988.
20. Aaronson, N. K., Calais da Silva, F., Yoshida, O., van Dam, F. S., Fosså, S. D., Miyakawa, M., Raghavan, D., Riedl, H., Robinson, M. R. and Worden, J. W.: Quality of life assessment in bladder cancer clinical trials: conceptual, methodological and practical issues. Prog. Clin. Biol. Res., 221: 149, 1986.
21. Moinpour, C. M., Feigl, P., Metch, B., Hayden, K. A., Meyskens, F. L., Jr. and Crowley, J.: Quality of life end points in cancer clinical trials: review and recommendations. J. Natl. Cancer Inst., 81: 485, 1989.
22. Witjes, J. A., v.d. Meijden, A. P., Witjes, W. P., Doesburg, W., Schaafsma, H. E. and Debruyne, F. M.: A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur. J. Cancer, 29A: 1672, 1993.
23. Richardson, J. L., Marks, G. and Levine, A.: The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J. Clin. Oncol., 6: 1746, 1988.
24. Yancik, R., Edwards, B. K. and Yates, J. W.: Assessing the quality of life of cancer patients: practical issues in study implementation. J. Psychosoc. Oncol., 7: 59, 1989.